A Nonrandomized Trial of Prolonged Exposure and Cognitive Processing Therapy for Combat-Related Posttraumatic Stress Disorder in a Deployed Setting.

Cognitive Processing Therapy Prolonged Exposure combat and operational stress reactions combat-related PTSD military deployments

Journal

Behavior therapy
ISSN: 1878-1888
Titre abrégé: Behav Ther
Pays: England
ID NLM: 1251640

Informations de publication

Date de publication:
11 2020
Historique:
received: 08 10 2019
revised: 24 12 2019
accepted: 03 01 2020
entrez: 14 10 2020
pubmed: 15 10 2020
medline: 5 2 2021
Statut: ppublish

Résumé

For many decades, the U.S. military's general operational guideline has been to limit the use of trauma-focused treatments for combat and operational stress reactions in military service members until they have returned from deployment. Recently, published clinical trials have documented that active-duty military personnel with combat-related posttraumatic stress disorder (PTSD) can be treated effectively in garrison. However, there are limited data on the treatment of combat and operational stress reactions or combat-related PTSD during military deployments. This prospective, nonrandomized trial evaluated the treatment of active-duty service members (N = 12) with combat and operational stress reactions or combat-related PTSD while deployed to Afghanistan or Iraq. Service members were treated by deployed military behavioral health providers using modified Prolonged Exposure (PE; n = 6) or modified Cognitive Processing Therapy (CPT; n = 6), with protocol modifications tailored to individual mission requirements. The PTSD Checklist-Military Version (PCL-M) total score was the primary outcome measure. Results indicated that both groups demonstrated clinically significant change in PTSD symptoms as indicated by a reduction of 10 points or greater on the PCL-M. Participants treated with modified PE had significant reductions in PTSD symptoms, t = -3.83, p = .01; g = -1.32, with a mean reduction of 18.17 points on the PCL-M. Participants treated with modified CPT had a mean PCL-M reduction of 10.00 points, but these reductions were not statistically significant, t = -1.49, p = .12; g = -0.51. These findings provide preliminary evidence that modified forms of PE and CPT can be implemented in deployed settings for the treatment of combat and operational stress reactions and combat-related PTSD.

Identifiants

pubmed: 33051031
pii: S0005-7894(20)30011-3
doi: 10.1016/j.beth.2020.01.003
pii:
doi:

Types de publication

Clinical Trial Journal Article Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

882-894

Informations de copyright

Copyright © 2020. Published by Elsevier Ltd.

Auteurs

Alan L Peterson (AL)

University of Texas Health Science Center at San Antonio; South Texas Veterans Health Care System, San Antonio; University of Texas at San Antonio. Electronic address: petersona3@uthscsa.edu.

Edna B Foa (EB)

University of Pennsylvania.

Patricia A Resick (PA)

Duke University.

Timothy V Hoyt (TV)

Defense Health Agency, Tacoma, WA.

Casey L Straud (CL)

University of Texas Health Science Center at San Antonio; University of Texas at San Antonio.

Brian A Moore (BA)

University of Texas Health Science Center at San Antonio; University of Texas at San Antonio.

James V Favret (JV)

United States Air Force.

Willie J Hale (WJ)

University of Texas Health Science Center at San Antonio; University of Texas at San Antonio.

Brett T Litz (BT)

VA Boston Healthcare System; Boston University.

Timothy E Rogers (TE)

Uniformed Services University of the Health Sciences; Wilford Hall Ambulatory Surgical Center, Joint Base San Antonio-Lackland, TX.

Jay M Stone (JM)

United States Air Force.

Robert Villarreal (R)

University of Texas Health Science Center at San Antonio.

Christopher S Woodson (CS)

United States Army.

Stacey Young-McCaughan (S)

University of Texas Health Science Center at San Antonio.

Jim Mintz (J)

University of Texas Health Science Center at San Antonio.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH